Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

<div>Chest CT scan. Chest CT scan performed on admission (a, b) four months after afatinib treatment (c) before the initiation of gefitinib (d) two months after gefitinib treatment (e) and six months after gefitinib treatment (f). Arrows indicate separate tumor nodules in the same lobe as the primary tumor.</div>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML 

Figure 1 | Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML 